Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 21, 2023 20:32 ET | Source: Roivant Sciences

Roivant Sciences Announces Change to its Board of Directors

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that its founder Vivek Ramaswamy has stepped down from the...
February 13, 2023 07:00 ET | Source: Roivant Sciences

Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update

$9.2M in net product revenue from VTAMA reported for the quarter ended December 31, 2022, with nearly 100,000 VTAMA prescriptions written by approximately 8,600 unique prescribers since launchVTAMA...
February 02, 2023 21:14 ET | Source: Roivant Sciences

Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced the pricing of an upsized underwritten public offering of...
February 01, 2023 16:05 ET | Source: Roivant Sciences

Roivant Sciences Announces Proposed Public Offering of Common Shares

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) announced today that it has commenced an underwritten public offering of $150...
January 30, 2023 08:00 ET | Source: Roivant Sciences

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023

Quarterly investor call and webcast scheduled on Monday, February 13 at 8:00 a.m. ETRoivant will also participate in the SVB Securities Global Biopharma Conference in February and the Cowen 43rd...
January 04, 2023 06:05 ET | Source: Roivant Sciences

Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker Positive Patient Populations

RVT-3101 demonstrated statistically significant and clinically meaningful efficacy at each dose testedAcross all patients treated with RVT-3101, the clinical remission and endoscopic improvement rates...
December 01, 2022 08:00 ET | Source: Roivant Sciences

Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases

Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody that blocks tumor necrosis factor-like ligand 1A (TL1A), a cytokine believed to play a key...
November 14, 2022 07:00 ET | Source: Roivant Sciences

Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update

Expected cash runway extended into the second half of calendar year 2025First major PBM/payer contract signed for VTAMA, effective October 1Over 54,000 VTAMA prescriptions written by approximately...
November 10, 2022 09:00 ET | Source: Roivant Sciences

Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC

NEW YORK and BASEL, Switzerland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Affivant, a biotechnology company dedicated to developing novel immune-oncology approaches to activate and enable the innate immune...
November 08, 2022 06:15 ET | Source: Roivant Sciences

Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the...